Crohn's Disease Associated Pyoderma Gangrenosum Treated with Adalimumab.
Pyoderma gangrenosum is a known, though infrequent, ulcerative skin lesion that is often associated with systemic inflammatory and immunologic diseases. Objective: To present the efficacy of Adalimumab, a fully human Tumour Necrosis Factor-á antagonist, in the treatment of pyoderma gangrenosum asso...
| Published in: | Balkan Medical Journal Vol. 29; no. 1; pp. 93 - 96 |
|---|---|
| Main Authors: | , , , , , |
| Format: | case study pictorial Journal Article |
| Published: |
Galenos Yayinevi Tic. LTD. STI
Mar2012
|
| Online Access: | View this record in EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=104568708&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 104568708 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 21463123 BM3Q jtl: Balkan Medical Journal issn: 21463123 maglogo: N pubinfo: dt: Mar2012 vid: 29 iid: 1 pid: 28155 pub: Galenos Yayinevi Tic. LTD. STI artinfo: ui: 104568708 75272639 10.5174/tutfd.2010.04446.1 104568708 ppf: 93 ppct: 3 formats: tig: atl: Crohn's Disease Associated Pyoderma Gangrenosum Treated with Adalimumab. aug: au: Kakagia, Despoina Efremidou, Eleni Lyratzopoulos, Nikolaos Mitrakas, Alexandros Pitiakoudis, Michael Kouklakis, George affil: Democritus University in Thrace Medical School, Plastic, Reconstructive Surgery, Alexandroupolis, Greece sug: subj: Crohn Disease Diagnosis Pyoderma Gangrenosum Drug Therapy Antibodies, Monoclonal Therapeutic Use Comorbidity Male Adult Immunologic Factors Tumor Necrosis Factor Time Factors Adult: 19-44 years Male ab: Pyoderma gangrenosum is a known, though infrequent, ulcerative skin lesion that is often associated with systemic inflammatory and immunologic diseases. Objective: To present the efficacy of Adalimumab, a fully human Tumour Necrosis Factor-á antagonist, in the treatment of pyoderma gangrenosum associated with Crohn's disease. Methods: A young male patient with pyoderma gangrenosum of the shin as the first sign of clinically active Crohn's disease, who was treated with Adalimumab, is herein presented. Results: Almost complete healing of the lesion was achieved after 12 weeks of treatment. Conclusions: Successful treatment outcome suggests that Adalimumab is not only a therapeutic option for Crohn's disease but may also be a safe and effective therapy for Pyoderma gangrenosum associated with the disease. Pyoderma gangrenosum should be suspected in any cutaneous ulcerative lesion occurring in patients with Crohn's disease. pubtype: Academic Journal doctype: case study pictorial Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|